Drug Shortages and Their Impact on Cardio-Oncology Care
In the dynamic world of healthcare, drug shortages pose a significant challenge, particularly within the specialised sector of cardio-oncology. This broadcast delves into the pressing issue of drug shortages and their profound implications on patient care at the intersection of cardiovascular disease and cancer.
This broadcast offers a platform for knowledge exchange, ensuring that healthcare professionals are well-equipped to navigate challenges, advocate for change and provide the best possible care for their cardio-oncology patients.
The partnership combines Radcliffe’s rapidly growing global community and expertise in delivering the most innovative virtual events, with the knowledge and experience of IC-OS’s members, to curate broadcasts that challenge current practice and have real-world patient benefits.
This broadcast is for cardiologists, haematologists, oncologists, nurse practitioners, nurses and pharmacists.
The International Cardio-Oncology Society is a committed group of professionals throughout the world who are striving to protect the cardiovascular health of all patients who are undergoing cancer therapy. By optimising the cardiac status of patients with cancer before, during and after their treatment, IC-OS is collectively improving the overall outcomes including survival and quality of life. IC-OS aims to provide the latest scientific and clinical education and research for anyone treating patients with cancer in the hopes of enhancing cardiovascular protection.
This is an independent activity run by the International cardio-oncology Society (ICOS) and co-produced in collaboration with Radcliffe Cardiology. IC-OS has been provided support to deliver this webinar series by AstraZeneca, BMS/Pfizer Alliance, Eli Lilly and Roche through an unrestricted educational grant to cover organisational costs and has had no input into the agenda or content of this educational activity. Radcliffe Cardiology has received no industry funding.
Sarah M Hayes
This broadcast is supported by
Prof Daniel Lenihan is a cardio-oncologist specialising in cardiology, heart disease and advanced heart failure, at Saint Francis Healthcare System, Cape Girardeau, US.
He is a co-Founder and Board Member of the International Cardio-Oncology Society (ICOS), which is an international professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.
He is actively involved in patient care as the Director of the Cardio-Oncology Programme, Cardiac Rehabilitation, and the Heart Failure clinic at Saint Francis Healthcare System.
Prof Joe Carver is the Bernard Fishman Clinical Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania, Philadelphia, US the Chief Operating Officer of the Abramson Family Cancer Research Institute and the Chief of Staff of the Abramson Cancer Center.
He is the Director of the Thalheimer Cardio-oncology Center at the Abramson Cancer Center and his clinical practice is in the subspecialty of cardio-oncology.
Dr Kristen Petersen is a Myeloma Clinical Oncology Pharmacist at Duke University Medical Center, Durham, US.
Sarah M Hayes
Dr Sarah is a Board-Certified Oncology Pharmacist serving as the Inpatient Hematology/Oncology preceptor at North Memorial Health, Minneapolis, US. She serves as a lecturer at the University of Minnesota College of Pharmacy. Sarah is an active member of HOPA (Hematology/Oncology Pharmacy Association), contributing to publications, new drug updates, and BCOP recertification courses.
Dr Katie Paxton is a 1st year Medical Affairs Fellow with PharmD and MBA at the University of Carolina, Eshelman School of Pharmacy, Chapel Hill, US.